CONFERENCE DAY ONE

Wednesday, May 28, 2025

7:30 am Check In & Morning Coffee

8:30 am Chair’s Opening Remarks

  • Mayssa Attar Senior Vice President & Head of Pharmaceutical, Consumer Research & Development, Bausch + Lomb

REVOLUTIONIZING OPHTHALMOLOGY THROUGH ARTIFICIAL INTELLIGENCE TO DETECT EARLIER VISION LOSS

9:00 am Panel Discussion: Delving into the Ethical, Economic & Legal Barriers to AI Algorithm Application in Ophthalmic Trials

  • Mohammad Eslami Instructor, Harvard Medical School
  • Mayssa Attar Senior Vice President & Head of Pharmaceutical, Consumer Research & Development, Bausch + Lomb
  • Touseef Qureshi Assistant Professor, Cedars-Sinai Medical Center

Synopsis

  • Addressing the complexity of sourcing and processing images from multiple providers while maintaining data integrity and compliance
  • Navigating patient privacy and data security
  • Exploring strategies to demonstrate the clinical validity of AI algorithms and secure Phase 3 trials and market approval

9:30 am Unearthing AI’s Impact on Clinical Retinal Studies to Elevate Outcomes From Recruitment to Results

Synopsis

  • Detailing the protocol design of AI-derived photoreceptor layer abnormalities as an inclusion criterion
  • Exploring AI-derived photoreceptor layer abnormalities as an endpoint
  • Utilizing microperimetry to establish ovel functional endpoints

10:00 am Unmasking Bias and Embracing Uncertainty with AI to Accelerate Ophthalmology

Synopsis

  • Discussing how biases impact diagnostic accuracy, particularly for underrepresented groups
  • Presenting current or emerging methods to identify and reduce bias, such as reweighting datasets or algorithmic fairness interventions
  • Proposing new ways to standardize datasets, external validations, or uncertainty metrics specific to ophthalmic AI

10:30 am Speed Networking

Synopsis

A prime chance to make the most of in-person networking with a niche community of ophthalmic professionals. Designed to maximize your introduction to numerous new individuals and serve as a catalyst for ongoing discussions during the summit.

11:00 am Morning Coffee Break

11:30 am Delving Into AI Screening for Clinical Trials

Synopsis

  • AI pre-screening of imaging criteria for retinal diseases can potentially reduce screen failures.
  • Automated imaging analysis streamlines patient stratification and trial enrollment, optimizing resource utilization.
  • Scalable, cost-effective AI solutions enhance workflow efficiency and data consistency in clinical trials.

12:00 pm Session Reserved for iCare

12:30 pm Predicting Pancreatic Cancer Using AI Analysis of Fundus Images of the Retina of Diabetic Patients to Allow for Earlier Detection

Synopsis

  • Exploring the potential presence of early signs of pancreatic cancer in the retina
  • Using AI to analyze retinal vessels and identify distinct features in diabetic individuals who may later develop pancreatic cancer
  • Developing an AI-based prediction model to forecast pancreatic cancer in diabetic patients by analyzing both retinal and pancreatic data which will eventually help detect cancer at early stages

1:00 pm Networking Lunch

INVESTIGATING THE LATEST ADVANCEMENTS WITH IMAGING BIOMARKERS TO SPEARHEAD DEVELOPMENT

2:00 pm Discussing the Technologies & Biomarkers Addressing Specific Disease States, with a Focus on Structural & Functional Biomarkers

  • M Francesca Cordeiro Professor Imperial College London, UCL, ICORG, Western Eye Hospital & Founder Novai Ltd, University College London - UCL

Synopsis

  • Summarizing the status of existing structural and functional endpoints in AMD
  • Predicting GA growth and direction of growth
  • Highlighting non-responders to therapy early in AMD treatment pathways

2:30 pm Roundtable: Exploring the State of Play with Biomarkers for AMD, GA & IRD

Synopsis

Join conversations with your fellow peers to discuss developments with structural and function biomarkers

for specific ophthalmic diseases

Moderator Feedback & Audience Debate

  • Moderators will be assigned to each roundtable to facilitate discussion and collate the findings
  • Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate

AMD | GA | IRD

3:00 pm Utilizing Delayed Near InfraRed Analysis To Identify Novel Features of Non-Exudative AMD in a Natural History Study

Synopsis

  • Interpreting cross-sectional and longitudinal multimodal images suggests that DNIRA provides a “functional footprint” of AMD
  • Addressing the “roadmap” from imaging to biomarker development
  • Considering the opportunities and challenges of integrating prospectively acquired, small datasets into AI-based biomarker development

3:30 pm Afternoon Break & Poster Session

Synopsis

Immerse yourself in an engaging and informal session, join your peers in a relaxed atmosphere that encourages meaningful conversions and relationship building. Explore a range of exciting poster presentations on the latest ophthalmic imaging biomarkers developments and utilize this opportunity to showcase your own innovations. To submit a poster for this session, please contact info@hansonwade.com.

PRECLINICAL DEVELOPMENTS TO ELEVATE TRANSLATIONAL CAPABILITIES TO PREVENT BLINDING DISEASES

4:00 pm Roundtable Discussion: Synergizing Molecular Imaging & Cross-Species Data to Achieve Alignment

Synopsis

A more practical and highly interactive breakout roundtable session where attendees can crowd-source solutions and share opinions on pre-assigned topic areas:

  • Advanced molecular imaging techniques to enhance understanding in smaller models
  • Standardizing data collection methods that align with clinical endpoints
  • Discussing the potential of automating analysis techniques to draw parallels between models

Moderator feedback & audience debate

  • Moderators will be assigned to each roundtable to facilitate discussion and collate the findings
  • Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate

4:30 pm Delving Into How Photopic Visual Function is Preserved in Retinal Remodeling

  • Cyril Eleftheriou Ex Instructor & Director of Imaging Core, Burke Neurological Institute, Weil Cornell Medicine

Synopsis

  • Utilizing a multi-dimensional map of pathophysiology for the P23H mouse model to identifying novel stages of dysfunction and physiological biomarkers
  • Overcoming dramatic and progressive photoreceptor loss with age, to achieve photopic measures of visual acuity and contrast sensitivity remained largely intact up to postnatal day (PND) 300
  • Detailing how hyperactive neuronal activity emerges before aberrant glial and vascular changes, and before the dramatic decline of photopic spatial visual function

5:00 pm End of Conference Day One & Chair’s Closing Remarks

  • Mayssa Attar Senior Vice President & Head of Pharmaceutical, Consumer Research & Development, Bausch + Lomb